Ann: Quarterly Activities and Cashflow Report, page-70

HYGEA purchase orders Medical Patch Potential patients >400,000 patients

HYGEA purchase orders Prizma potential Approx 3.3m patients

Guangzhou China Production Capacity
CFDA, FDA, CE

IDTF USA Patients monitoring 1-30 days. Potentially years for chronic care services. Medicare rebates are expected during 2019.

Nasdaq Listing
US prospectus public in coming weeks e.g. May 2019.

HKSE Listing
Anticipated within 3rd Quarter 2019 e.g. Sept 2019

UK
G Medical Patch completed pilot program and is now moving to expanding the programs as well as commercializing multiple accounts with its afficiates.

Yacov Geva Loan Agreement
The board of directors thanks Dr Geva and this exemplifies the continued support and faith the CEO has in the future of the company. The conversion of the portion of the loan into shares is anticipated shortly.

Board appointment
World renowned Cardiologist Professor Zeev Rothstein to the Board of Directors.

CFDA
Granted Green Channel
Prizma Additional work is currently being finalised to be finalized in May 2019 and will form part of final regulatory documentation.
G Medical Patch is in progress with regulatory process.

DYOR.

My opinion:
CFDA GM Patch could be approved by June 2019.
CFDA Prizma could be approved by July 2019.
Nasdaq Listing could be July 2019

02 Nov 2018 update
The Telerhythmics acquisition will substantially increase insurance coverage and create a distinct competitive advantage providing G Medical 100 commercial payor across national markets and additional 30-35 million covered lives. With the company's aggregated sum increasing to 100 million lives. G Medical will also gain access to several large health systems and large urance providers.

Its appears G Medical will do Nasdaq Listing with or without CFDA as they are confident with IDTF (Independent Diagnostic Testing Facility)

I am very happy with my own research. Looking forward for GMV this year.